etoposide has been researched along with rrx-001 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JF; Brzezniak, C; Cabrales, P; Caroen, S; Carter, CA; Day, R; Dean Abrouk, N; Degesys, A; Kim, MM; Larson, C; Oronsky, A; Oronsky, B; Reid, TR; Scicinski, J | 1 |
| Abrouk, N; Brown, B; Burbano, E; Caroen, S; Carter, CA; Coyle, A; Ferry, L; Larson, C; Oronsky, A; Oronsky, B; Quinn, M; Reid, TR; Scribner, CL; Thilagar, B; Varner, G | 1 |
1 trial(s) available for etoposide and rrx-001
| Article | Year |
|---|---|
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitro Compounds; Small Cell Lung Carcinoma; Treatment Outcome; Young Adult | 2019 |
1 other study(ies) available for etoposide and rrx-001
| Article | Year |
|---|---|
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Nitro Compounds; Treatment Outcome | 2016 |